A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18

Expert Rev Vaccines. 2012 Apr;11(4):395-406. doi: 10.1586/erv.12.20.

Abstract

Human papillomavirus infection causes cervical cancer, a significant portion of anal, genital and oropharyngeal cancers, genital warts and recurrent respiratory papillomatosis. In June 2006, a quadrivalent human papillomavirus-6/11/16/18 vaccine (GARDASIL/SILGARD®; Merck, NJ, USA) was licensed in the USA; subsequent approval has been granted in the EU (September 2006). It has since been approved in 121 countries with over 74 million doses distributed globally as of March 2011.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Condylomata Acuminata / epidemiology
  • Condylomata Acuminata / prevention & control
  • Condylomata Acuminata / virology
  • Drug Approval
  • European Union
  • Female
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Humans
  • Male
  • Oropharyngeal Neoplasms / epidemiology
  • Oropharyngeal Neoplasms / prevention & control
  • Oropharyngeal Neoplasms / virology
  • Papilloma / epidemiology
  • Papilloma / prevention & control
  • Papilloma / virology
  • Papillomaviridae / immunology*
  • Papillomavirus Infections / complications*
  • Papillomavirus Infections / epidemiology
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Infections / virology
  • Papillomavirus Vaccines / administration & dosage*
  • Papillomavirus Vaccines / immunology*
  • United States
  • Uterine Cervical Neoplasms / epidemiology*
  • Uterine Cervical Neoplasms / prevention & control*
  • Uterine Cervical Neoplasms / virology
  • Vaccination / methods

Substances

  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Papillomavirus Vaccines